시장보고서
상품코드
1672845

양성자 펌프 억제제 시장 : 유형별, 적응 질환별, 제형별, 유통 채널별, 지역별

Proton Pump Inhibitors Market, By Type, By Disease Indication, By Dosage Form, By Distribution Channel, By Geography

발행일: | 리서치사: Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

양성자 펌프 억제제 세계 시장은 2025년에는 40억 2,000만 달러, 2032년에는 59억 달러에 이르고, 2025-2032년 연평균 복합 성장률(CAGR) 5.6%로 성장할 것으로 예측됩니다.

보고 범위 보고서 세부정보
기준연도 2024년 2025년 시장 규모 40억 2,000만 달러
실적 데이터 2020-2024년 예측 기간 2025-2032년
예측 기간(2025-2032년) CAGR: 5.60% 2032년 가치 예측 59억 달러
그림. 양성자 펌프 억제제 시장 점유율(%), 2025년 지역별
Proton Pump Inhibitors Market-IMG1

양성자 펌프 억제제(PPI)는 위에서 생산되는 산의 양을 줄임으로써 작용하는 의약품 그룹입니다. PPI는 일반적으로 산성 역류, 궤양, 식도 염증의 치료에 사용됩니다. PPI는 위의 위벽 세포의 표면에 있는 효소, 양성자 펌프의 작용을 저해함으로써 효과를 발휘합니다. 이 효소는 위에서 염산의 생성을 돕는 이온의 수송을 담당합니다. 이 펌프를 억제함으로써 PPI는 산의 생산을 감소시키고 위산 과다로 인한 증상을 완화합니다. 산 관련 질환의 유병률 증가, 이러한 질병으로 고통받는 노인 인구 증가, 건강 관리 지출 증가는 가까운 미래에 세계 양성자 펌프 억제제 시장의 성장을 가속할 수 있습니다.

시장 역학:

소화성 궤양 질환 및 위식도 역류증(GERD)과 같은 산 관련 질환의 세계 유병률이 증가하면 양성자 펌프 억제제 세계 시장 성장이 이어질 수 있습니다. 식생활의 변화와 라이프 스타일의 변화로 인해 GERD는 세계에서 매우 널리 사용되고 있습니다. 한 추계에 따르면 북미에서는 인구의 20% 이상이 GERD를 앓고 있습니다. 양성자 펌프 억제제는 GERD 환자의 첫 번째 선택 약물입니다. 고령자는 산 관련 질환에 걸리기 쉽기 때문에 노인 인구 증가도 시장 성장의 원동력이 됩니다. 그러나 신장 장애, 골절, 폐렴, 영양소의 흡수 억제와 같은 PPI의 장기 사용과 관련된 부작용은 시장 성장을 방해할 수 있습니다. 소화기계의 건강에 대한 의식 증가와 신흥국의 의료비 증가는 시장 기업에게 기회를 제공할 수 있습니다.

본 조사의 주요 특징

  • 본 보고서에서는 세계 양성자 펌프 억제제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모(10억 달러) 및 복합 연간 성장률(CAGR%)을 제공합니다.
  • 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 행렬을 설명합니다.
  • 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
  • 엔터프라이즈 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 매개변수를 기반으로 세계 양성자 펌프 억제제 시장의 주요 기업을 프로파일링합니다.
  • 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
  • 세계 양성자 펌프 억제제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
  • 이해관계자는 세계 양성자 펌프 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사 결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 전망

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 억제요인
    • 기회
  • 영향 분석
  • 시장 동향
  • 주요 발전
  • 규제 시나리오
  • 인수와 제휴 시나리오
  • 자금 조달 및 투자
  • PEST 분석
  • Porter's Five Forces 분석

제4장 세계의 양성자 펌프 억제제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

  • 전체적인 영향
  • 정부의 대처
  • COVID-19에 의한 시장에 대한 영향

제5장 세계의 양성자 펌프 억제제 시장, 유형별, 2020년-2032년,(10억 달러)

  • 오메프라졸
  • 판타프라졸
  • 라베프라졸
  • 데키란소프라졸
  • 란소프라졸
  • 기타

제6장 세계의 양성자 펌프 억제제 시장, 질환 적응증별, 2020년-2032년,(10억 달러)

  • 궤양
  • 위식도 역류증
  • 기타

제7장 세계의 양성자 펌프 억제제 시장, 제형별, 2020년-2032년,(10억 달러)

  • 정제
  • 캡슐
  • 주사
  • 기타

제8장 세계의 양성자 펌프 억제제 시장, 제형별, 2020년-2032년,(10억 달러)

  • 병원 약국
  • 소매 약국
  • 온라인 약국

제9장 세계의 양성자 펌프 억제제 시장, 지역별, 2020년-2032년,(10억 달러)

  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제10장 경쟁 구도

  • 기업 프로파일
    • AstraZeneca
    • Pfizer
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Procter &Gamble
    • Johnson &Johnson
    • GlaxoSmithKline plc
    • Bayer AG
    • Eisai Co., Ltd.
    • Merck &Co., Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Sun Pharmaceutical Industries Ltd.
    • Allergan, Inc.
    • Cadila Pharmaceuticals
    • Daiichi Sankyo Company, Limited
    • Perrigo Company PLC.

제11장 분석가 추천

  • 기회
  • 애널리스트의 견해
  • Coherent Opportunity Map

제12장 참고문헌과 조사방법

  • 참고문헌
  • 조사 방법
SHW 25.04.11

Global Proton Pump Inhibitors Market is estimated to be valued at USD 4.02 Bn in 2025 and is expected to reach USD 5.90 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 4.02 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.60% 2032 Value Projection: USD 5.90 Bn
Figure. Proton Pump Inhibitors Market Share (%), By Region 2025
Proton Pump Inhibitors Market - IMG1

Proton pump inhibitors (PPIs) are a group of medicines that work by reducing the amount of acid produced in the stomach. PPIs are commonly used to treat acid reflux, ulcers, and inflammation of the esophagus. These work by blocking the action of the proton pump, an enzyme on the surface of gastric parietal cells. This enzyme is responsible for transportation of ions that aid in the production of hydrochloric acid in the stomach. By inhibiting this pump, PPIs decrease acid production and offer relief from conditions caused by excess stomach acid. Growing prevalence of acid related diseases, increasing aging population suffering from such diseases, rising healthcare expenditure can drive the global proton pump inhibitors market growth in the near future.

Market Dynamics:

Rising prevalence of acid-related diseases such as peptic ulcer disease and gastroesophageal reflux disease (GERD) around the world can drive the global proton pump inhibitors market growth. GERD has become highly common worldwide due to changing dietary patterns and lifestyle changes. According to some estimates, GERD affects over 20% of the population in North America. Proton pump inhibitors are first line treatment for GERD patients. Growing geriatric population can also drive the market growth as older people are more prone to acid-related disorders. However, side effects associated with long-term PPI usage such as kidney problems, bone fractures, pneumonia, and interference with absorption of nutrients can hamper the market growth. Growing awareness regarding digestive health and rising healthcare expenditure in emerging nations can offer opportunities for the market players.

Key Features of the Study:

  • This report provides in-depth analysis of the global proton pump inhibitors market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global proton pump inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AstraZeneca, Pfizer, Johnson and Johnson, and Bayer
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global proton pump inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitors market

Detailed Segmentation-

  • By Type
    • Omeprazole
    • Pantaprazole
    • Rabeprazole
    • Dexlansoprazole
    • lansoprazole
    • Others
  • By Disease Indication
    • Ulcers
    • Gastroesophageal Reflux Disease
    • Others
  • By Dosage Form
    • Tablet
    • Capsules
    • Injection
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca
    • Pfizer
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Procter & Gamble
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Bayer AG
    • Eisai Co., Ltd.
    • Merck & Co., Inc.
    • Reddy's Laboratories Ltd.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Sun Pharmaceutical Industries Ltd.
    • Allergan, Inc.
    • Cadila Pharmaceuticals
    • Daiichi Sankyo Company, Limited
    • Perrigo Company PLC

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Disease Indication
    • Market Snapshot, By Dosage Form
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Proton Pump Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Proton Pump Inhibitors Market, By Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Omeprazole
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pantaprazole
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rabeprazole
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Dexlansoprazole
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Lansoprazole
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Proton Pump Inhibitors Market, By Disease Indication, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Ulcers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Gastroesophageal Reflux Disease
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Proton Pump Inhibitors Market, By Dosage Form, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Tablet
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Capsules
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Injection
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Proton Pump Inhibitors Market, By Dosage Form, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Proton Pump Inhibitors Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • AstraZeneca
      • Company Highlights
      • Disease Indication Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer
      • Company Highlights
      • Disease Indication Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Procter & Gamble
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Bayer AG
    • Eisai Co., Ltd.
    • Merck & Co., Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Sun Pharmaceutical Industries Ltd.
    • Allergan, Inc.
    • Cadila Pharmaceuticals
    • Daiichi Sankyo Company, Limited
    • Perrigo Company PLC.

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. Reference and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제